RIGL Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 31.72%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Eli Lilly & Co.'s return on equity of 106.26%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $49.60, signalling upside risk potential of 4.69%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,056.70 which suggests that it could grow by 4.16%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.026% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 7.68x while Eli Lilly & Co.'s PE ratio is 50.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 3.09x versus 15.57x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of -255.85%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $49.60, signalling upside risk potential of 4.69%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.026% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 7.68x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 3.09x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 7.53%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat PTC Therapeutics, Inc.'s return on equity of --.

Rigel Pharmaceuticals, Inc. has a consensus price target of $49.60, signalling upside risk potential of 4.69%. On the other hand PTC Therapeutics, Inc. has an analysts' consensus of $81.86 which suggests that it could grow by 5.15%. Given that PTC Therapeutics, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe PTC Therapeutics, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.026% more volatile than S&P 500. In comparison PTC Therapeutics, Inc. has a beta of 0.470, suggesting its less volatile than the S&P 500 by 52.999%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. PTC Therapeutics, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than PTC Therapeutics, Inc. quarterly revenues of $211M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is higher than PTC Therapeutics, Inc.'s net income of $15.9M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 7.68x while PTC Therapeutics, Inc.'s PE ratio is 9.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 3.09x versus 3.60x for PTC Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 34.76%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $49.60, signalling upside risk potential of 4.69%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $485.36 which suggests that it could grow by 6.12%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.026% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 7.68x while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 3.09x versus 10.10x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.